stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) EBITDA
Halozyme Therapeutics, Inc.'s EBITDA for fiscal 2025 was $561.3M, down 10.8% from $629.2M in fiscal 2024. Over the twelve months to 30 June 2026 it was $719.2M. Over the past ten years it has ranged from −$68.5M (fiscal 2018) to $629.2M (fiscal 2024); the current reading is higher than 91% of that period. Halozyme Therapeutics, Inc. ranks 11th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $561.3M | (10.80%) |
| FY2024 | $629.2M | 48.61% |
| FY2023 | $423.4M | 29.84% |
| FY2022 | $326.1M | 14.51% |
| FY2021 | $284.8M | 75.25% |
| FY2020 | $162.5M | — |
| FY2019 | −$63.5M | — |
| FY2018 | −$68.5M | — |
| FY2017 | $84.6M | — |
| FY2016 | −$67.6M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $323.3M | 46.63% |
| Mar 2026 | $220.5M | — |
| Dec 2025 | −$64.4M | — |
| Sep 2025 | $239.8M | 7.23% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $1.1B |
| EXEL Exelixis, Inc. compare | $1.0B |
| HALO Halozyme Therapeutics, Inc. | $719.2M |
| BMRN BioMarin Pharmaceutical Inc. compare | $374.0M |
| TECH Bio-Techne Corp compare | $349.2M |
| ASND Ascendis Pharma A/S compare | $321.3M |
| BBIO BridgeBio Pharma, Inc. compare | −$352.4M |
| KYMR Kymera Therapeutics, Inc. compare | −$405.5M |
| SMMT Summit Therapeutics PLC compare | −$872.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on HALO
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement